Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$1.01 - $1.42 $60,660 - $85,285
60,060 New
60,060 $67,000
Q3 2022

Nov 14, 2022

SELL
$0.45 - $13.0 $45,000 - $1.3 Million
-100,000 Reduced 41.67%
140,000 $88,000
Q2 2022

Aug 15, 2022

SELL
$0.43 - $0.91 $4,300 - $9,100
-10,000 Reduced 4.0%
240,000 $117,000
Q1 2022

May 16, 2022

SELL
$0.67 - $1.39 $65,124 - $135,108
-97,200 Reduced 28.0%
250,000 $208,000
Q4 2021

Feb 14, 2022

BUY
$1.18 - $2.18 $269,419 - $497,741
228,322 Added 192.06%
347,200 $441,000
Q2 2021

Aug 16, 2021

SELL
$1.87 - $2.7 $84,150 - $121,500
-45,000 Reduced 27.46%
118,878 $240,000
Q1 2021

May 17, 2021

SELL
$2.06 - $3.01 $247,162 - $361,145
-119,982 Reduced 42.27%
163,878 $436,000
Q4 2020

Feb 16, 2021

BUY
$1.99 - $3.25 $212,643 - $347,282
106,856 Added 60.37%
283,860 $568,000
Q2 2020

Aug 14, 2020

BUY
$2.39 - $4.0 $119,500 - $200,000
50,000 Added 39.37%
177,004 $653,000
Q1 2020

May 15, 2020

BUY
$1.74 - $4.26 $41,276 - $101,055
23,722 Added 22.97%
127,004 $315,000
Q4 2019

Feb 14, 2020

BUY
$1.77 - $3.84 $15,753 - $34,176
8,900 Added 9.43%
103,282 $397,000
Q1 2019

May 15, 2019

BUY
$2.35 - $3.27 $70,500 - $98,100
30,000 Added 46.6%
94,382 $250,000
Q4 2018

Feb 14, 2019

SELL
$2.1 - $4.5 $240,697 - $515,781
-114,618 Reduced 64.03%
64,382 $151,000
Q3 2018

Nov 13, 2018

BUY
$3.7 - $5.25 $314,500 - $446,250
85,000 Added 90.43%
179,000 $788,000
Q4 2017

Feb 14, 2018

BUY
$6.35 - $8.75 $158,750 - $218,750
25,000 Added 36.23%
94,000 $639,000
Q3 2017

Nov 14, 2017

BUY
$5.75 - $8.1 $396,750 - $558,900
69,000
69,000 $559,000

About Cidara Therapeutics, Inc.


  • Ticker CDTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,075,696
  • Market Cap $1.63B
  • Description
  • Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...
More about CDTX
Track This Portfolio

Track Bridgeway Capital Management, LLC Portfolio

Follow Bridgeway Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgeway Capital Management, LLC with notifications on news.